Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Costs for generic hepatitis C drugs available in India would be paid back in 5 to 10 years

Use of the generic versions of directly-acting antiviral drugs that are available in India to treat hepatitis C virus infection is not only cost effective but actually saves lifetime costs for treating infected patients in that country.

Published
18 May 2017
From
Eurekalert Inf Dis
Surgeons plan to use hepatitis-infected hearts to slash wait for a transplant

As many as 1,000 such infected kidneys are thrown away each year in the United States, but new medications have made hepatitis C curable — and made it possible to consider using infected organs for transplants. That could cut down on the wait time not just for kidneys but also other organs, especially hearts.

Published
15 May 2017
From
STAT
State HCV Incidence and Policies Related to Preventive Services, and Treatment Services for Persons Who Inject Drugs

The authors of this analysis examined state laws governing access to safe infection equipment and Medicaid policies related to HCV treatment for people who inject drugs (PWID) in all 50 states and DC.

Published
12 May 2017
From
CDC
US: New Hepatitis C Infections Nearly Tripled over Five Years

Over just five years, the number of new hepatitis C virus infections reported to CDC has nearly tripled, reaching a 15-year high, according to new preliminary surveillance data released today by the Centers for Disease Control and Prevention (CDC).

Published
12 May 2017
From
CDC
Early Access to Medicines Scheme (EAMS) Granted to AbbVie’s Investigational Pan-genotypic Regimen for Chronic Hepatitis C in UK

The UK scheme makes glecaprevir/pibrentasvir available to people with compensated cirrhosis and prior treatment with an NS5A inhibitor (genotypes 1, 4, 5 or 6), chronic kidney disease (genotypes 2, 3, 5 or 6) or genotype 3 with previous exposure to pegylated interferon, ribavirin and/or sofosbuvir.

Published
10 May 2017
From
AbbVie press release
HIV blood disaster: UK families search for the truth

Jason Evans says his father was killed by contaminated blood that the government "knew was dangerous". In what is understood to be the first case of its kind, Jason is taking legal action against the government for its role in his father's death. More than 2,000 people – mostly haemophiliacs – have died after being infected with HIV and hepatitis C through blood treatments in the 1980s.

Published
10 May 2017
From
BBC
BC-developed hepatitis C screening test personalizes treatment for patients

Scientists in Vancouver have developed a new screening tool that reveals the genetic signature of an individual’s hepatitis C virus so that doctors can customize their treatment.

Published
10 May 2017
From
The Globe and Mail
Study points to new approach to battling hepatitis C infections

An international study led by researchers at Monash University's Biomedicine Discovery Institute (BDI) has shone light on the way the Hepatitis C Virus (HCV) hijacks the communication systems in the host cells it infects, uncovering potential new therapeutic targets for the disease.

Published
08 May 2017
From
Eurekalert
Besifovir and tenofovir exalidex look promising as new hepatitis B drugs

Two investigational nucleotide analogue antivirals were shown to be active against hepatitis B virus (HBV) with minimal potential for kidney and bone toxicity, researchers reported at the International

Published
08 May 2017
By
Liz Highleyman
Louisiana proposes tapping a century-old patent law to cut hepatitis C drug prices

Continuing public concerns over high-priced hepatitis C drugs are taking a new twist as Louisiana’s top health official proposes using an obscure federal patent law to get the medicines at a much lower cost. If successful, other states could reap the benefits.

Published
03 May 2017
From
Washington Post

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.